CA
NZ
UK
AU
IND
US
GAAP net income was USD 9.0 million, or USD 0.24 per diluted share, versus USD 8.4 million, or USD 0.21. The company said the per-share gain also reflects a lower share count after it redeemed its Series A-2 Preferred Stock last year and repurchased …
Selling, general and administrative expenses rose 3.2% to USD 177.6 million, which the company attributed mainly to merger transaction costs. Net interest expense fell to USD 12.9 million from USD 14.1 million. The Other, net line swung to a USD 1.0 million gain from …
The loss from continuing operations was USD 35.6 million, or USD 0.05 per share, compared with USD 32.9 million, or USD 0.04. Operating loss narrowed to USD 31.4 million asResearch and Developmentrose to USD 32.2 million. Discontinued operations lost USD 18.0 million after earning …
The geothermal Electricity segment slipped 2.1% to USD 163.7 million, with gross margin down 330 basis points to 22.2%. Management attributed the decline mainly to lower generation at Puna after a hurricane-related forced outage, partly offset by the July start of the 10 MW …
Key HighlightsNet asset value per share was USD 16.62 at September 30, 2026, down from USD 17.33 at December 31, 2025, while the filing shows a period-endMarket Valueof USD 9.81 per share.Third-quarter netInvestmentincome after taxes was USD 130.6 million, flat on USD 130.6 million …
GAAP gross margin was 33% against 41%, and non-GAAP gross margin was 36% against 42%, which the company tied to higher memory costs and VegaManufacturingtransition costs.GAAPoperating expenses fell to USD 50.5 million from USD 54.8 million, and non-GAAP operating expenses fell to USD 47.0 …
Gross profit rose 7% to USD 128.5 million, lifting gross margin 30 basis points to 33.2%. Selling, general and administrative expenses climbed USD 10.4 million, partly because last year's figure was reduced by USD 3.8 million of insurance proceeds. Excluding such items, the company …
Non-GAAP earnings grew much faster than the GAAP figure. Non-GAAP net income of USD 150.0 million, or USD 3.37 per diluted share, adds back items such as non-cash stock-based compensation, net of tax, and compares with USD 109.6 million, or USD 1.94, a year …
Cost of operations rose about USD 3.5 million to USD 30.8 million as production fell and onsite compounding added USD 3.1 million of costs. Selling, general and administrative expenses dropped USD 4.9 million to USD 7.8 million, helped by about USD 3.0 million of …
Manufacturing costs rose USD 20.2 million, which the filing ties to activity supporting potential future commercial launches. Clinical trial costs rose USD 18.7 million on the OPUS-1, OPUS-2 and OPUS-3 Phase 3 studies. Vaxcyte develops broad-spectrum pneumococcal conjugate vaccines using a cell-free protein synthesis …
Please wait processing your request...